Medtronic Plc
MDT
Market Cap$109.11B
Close$
Earnings Call Q3 2024
February 20, 2024 - AI Summary
Medtronic reported solid Q3 results with revenue growth of 4.6% and adjusted EPS of $1.30, beating expectations.
The company saw strong performance in multiple businesses, including Core Spine, Cardiac Surgery, Structural Heart, and Cardiac Pacing.
Diabetes business showed double-digit growth, driven by the global adoption of the MiniMed 780G system. In the US, the business returned to growth, growing mid-single-digits.
Exclusive for Stockcircle Pro members
Sign up
$91.55
15.6% upside
Current Fair Value
15.6% upsideUndervalued by 15.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $109.11 Billion |
|---|---|
| Enterprise Value | $125.97 Billion |
| Dividend Yield | $2.7259 (3.32%) |
| Earnings per Share | $3.15 |
| Beta | 0.54 |
| Outstanding Shares | 1,327,822,539 |
| Avg 30 Day Volume | 6,596,370 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 25.97 |
|---|---|
| PEG | 317.3 |
| Price to Sales | 3.3 |
| Price to Book Ratio | 2.03 |
| Enterprise Value to Revenue | 3.9 |
| Enterprise Value to EBIT | 20.51 |
| Enterprise Value to Net Income | 29 |
| Total Debt to Enterprise | 0.2 |
| Debt to Equity | 0.49 |
Revenue Sources
No data
ESG Score
No data
About Medtronic Plc
CEO: Geoffrey Martha